POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for myelofibrosis patients: tasquinimod trial launches
Disease control Recruiting nowThis study tests a drug called tasquinimod, given alone or with another drug (ruxolitinib), to see if it can help control myelofibrosis—a serious bone marrow disorder. About 33 adults with primary or related forms of myelofibrosis who have not responded to or cannot take standard…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:28 UTC
-
New hope for myelofibrosis patients who fail standard therapy
Disease control Recruiting nowThis early-phase study tests a new daily pill, AJ1-11095, in adults with myelofibrosis (a rare bone marrow cancer) whose disease has not responded or has returned after standard JAK2 inhibitor treatment. The main goals are to check safety, find the best dose, and see if it can re…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:23 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutatio…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Blood cancer drug bomedemstat gets Long-Term safety check in 400 patients
Disease control Recruiting nowThis study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 08:31 UTC
-
New registry study aims to map Real-World care for myelofibrosis anemia
Knowledge-focused Recruiting nowThis study is a registry that will follow 200 people in Germany with myelofibrosis and anemia. It will collect information on which treatments are used, how well they work, and how patients feel. The goal is to better understand current care and outcomes, not to test a new drug.
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 26, 2026 08:28 UTC